The trial, which involves approximately 300 adults, marks the first time a MoDE (Molecular Degrader of Extracellular proteins) platform therapy has reached this stage of clinical development. Unlike current standards of care—such as surgery, radioactive iodine, or antithyroid medications—BHV-1300 leverages the body's natural hepatic clearance pathways to selectively eliminate TSHR-IgG1 autoantibodies. These pathogenic proteins are responsible for overstimulating the thyroid receptor, driving hyperthyroidism and associated complications like thyroid eye disease.
Biohaven Launches Pivotal Phase 3 Trial for Graves' Disease Therapy
Biohaven has enrolled the first patient in a pivotal Phase 3 clinical trial of BHV-1300, a novel extracellular protein degrader designed to treat Graves' disease. By targeting the underlying autoantibodies rather than suppressing thyroid function, the drug aims to provide the first new therapeutic option for the condition in seventy years.
Early data from Phase 1b testing provided a foundation for the current study, showing that the molecule reduced pathogenic autoantibodies by more than 80% while normalizing thyroid hormone levels. The drug is administered via a self-operated autoinjector, offering a departure from traditional clinical interventions. If successful, the treatment would represent a significant shift in precision immunology, moving away from symptom management toward the direct removal of the specific proteins causing the autoimmune disorder.
Comments (0)
No comments yet. Be the first!